Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in
Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph t
Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Thera
Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87
Seagen hasn't let a pending acquisition by Pfizer interrupt its business development activities, adding to its pipeline with a wide-ranging partnership with Nurix Therapeu
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh